biocompatabity.ppt
•Download as PPT, PDF•
0 likes•4 views
The document discusses the biocompatibility of dental materials. It defines biocompatibility as materials being harmonious with life and not having toxic or injurious effects on biologic functions. Any material used in the body for any period of time as part of a medical treatment is considered a biomaterial. Standards and regulations from organizations like the FDA and ISO have been introduced to ensure the biocompatibility and safety of dental materials. A variety of tests are used to evaluate the biocompatibility of new materials, including primary tests, secondary tests, and usage tests. Chronic exposure to beryllium can cause berylliosis, a serious lung disease, so protective masks and gloves should be worn when working with b
Report
Share
Report
Share
Recommended
present scenario of clinical trials in India
this ppt talks about the clinical trends and growth in past 10 years and regulatory aspects of Clinical trials in India
Agreeing what outcomes to measure
1) The document discusses the importance of developing core outcome sets (COS) for clinical trials through consensus processes that meaningfully incorporate input from patients. COS ensure consistency across trials by specifying a minimum set of outcomes to measure.
2) Involving patients in determining what health outcomes to measure in COS is crucial because patients can identify which outcomes have the greatest impact on their lives. Their input also helps prevent selective reporting of outcomes in trials.
3) Developing COS through consensus processes that engage patients, healthcare providers, and other stakeholders from the beginning can launch trials with outcomes relevant to all groups. This maximizes the usefulness of research data.
Pharma Asia Newsletter Launched
The document proposes a supplier qualification policy and procedure for active pharmaceutical ingredients (APIs) in Pakistan. The policy aims to provide clear guidance on qualifying API suppliers to ensure quality and avoid risks to finished drug products. It outlines responsibilities, procedures for pre-audit assessment, onsite inspections, and post-audit evaluation to verify that suppliers meet standards. The procedures are intended to help regulators and manufacturers maintain quality and safety throughout the supply chain.
Personal Profile- Dr. Puneet 6th Nov Final
Dr. Puneet Kalra is a medical doctor seeking a role with a growth-oriented organization. He has 15 years of experience in clinical practice, research, and the pharmaceutical industry. His experience includes medical affairs, pharmacovigilance, quality management, product launches, and market access. He has contributed to scientific publications and received several awards for his performance and leadership.
Research and Development by Bishnu Adhikari
The document discusses the key steps involved in research and development of new medicines. It involves several years of pre-clinical and clinical testing to determine safety, efficacy, appropriate dosage form and marketing strategy. The process includes discovery of new compounds, laboratory and animal testing to determine toxicity and pharmacokinetics, followed by three phases of human clinical trials of increasing sample size. In parallel, development activities such as formulation, manufacturing, packaging and regulatory approval are also undertaken to commercialize the new medicine if clinical trials are successful. The overall process typically takes 12-15 years to develop a new medicine from initial research to market availability.
Harmonization of Approaches for Food Ingredients and Constituents: Is It Poss...
Harmonization of Approaches for Food Ingredients and Constituents: Is It Poss...Burdock Group Consultants
Presented by Dr. Ray Matulka at IFT15 on Sunday, July 12 at 1:15 PM.
The basic principles of safety can apply to all constituents in foods and beverages whether they are present purposefully or not. However, numerous factors can influence the approaches utilized for hazard characterization and risk assessment for various food and beverage constituents. These factors can include; the regulatory and legal framework being followed, what is and what is not known scientifically about the safety of a constituent, what the substance is and its function in a food or beverage, and consumer perception of the substance in the food or beverage. Simply segregating the safety assessment of compounds found in foods and beverages based how they came to be present in foods and beverages can be problematic for all stakeholders charged with ensuring the safety of foods and beverages. Additionally, food safety organizations around the world have adopted a variety of different approaches for addressing the safety of constituents in foods and beverages, which complicates, rather than simplifies the risk assessment process. The ability to adopt and adapt various scientifically valid approaches for evaluating safety becomes important for ensuring the safety and continuity of supply of foods and beverages. Another important factor that must be considered while evaluating the safety of constituents in food and beverages is communication with the consumer and crafting appropriate messaging demonstrating the rigor of the evaluation with a goal of preserving and promoting trust in the safety of the food and beverage supply.Vitargent introduction20130507
Vitargent is a Hong Kong-based biotechnology company that provides testing services and products to assess the impact of estrogenic chemicals and other pollutants. It has established several reference cases working with cosmetics companies and testing labs. Vitargent launched an "estrogen safe mark" and obtained accreditation making it the only lab in Asia that can provide certain toxicity testing. It is seeking strategic partners to help promote its programs, develop testing standards, and potentially pursue an IPO. Vitargent's services and products assess chemicals/pollutants like dioxins and it utilizes transgenic fish models to detect estrogenic substances in products like food, drugs, and the environment.
Recommended
present scenario of clinical trials in India
this ppt talks about the clinical trends and growth in past 10 years and regulatory aspects of Clinical trials in India
Agreeing what outcomes to measure
1) The document discusses the importance of developing core outcome sets (COS) for clinical trials through consensus processes that meaningfully incorporate input from patients. COS ensure consistency across trials by specifying a minimum set of outcomes to measure.
2) Involving patients in determining what health outcomes to measure in COS is crucial because patients can identify which outcomes have the greatest impact on their lives. Their input also helps prevent selective reporting of outcomes in trials.
3) Developing COS through consensus processes that engage patients, healthcare providers, and other stakeholders from the beginning can launch trials with outcomes relevant to all groups. This maximizes the usefulness of research data.
Pharma Asia Newsletter Launched
The document proposes a supplier qualification policy and procedure for active pharmaceutical ingredients (APIs) in Pakistan. The policy aims to provide clear guidance on qualifying API suppliers to ensure quality and avoid risks to finished drug products. It outlines responsibilities, procedures for pre-audit assessment, onsite inspections, and post-audit evaluation to verify that suppliers meet standards. The procedures are intended to help regulators and manufacturers maintain quality and safety throughout the supply chain.
Personal Profile- Dr. Puneet 6th Nov Final
Dr. Puneet Kalra is a medical doctor seeking a role with a growth-oriented organization. He has 15 years of experience in clinical practice, research, and the pharmaceutical industry. His experience includes medical affairs, pharmacovigilance, quality management, product launches, and market access. He has contributed to scientific publications and received several awards for his performance and leadership.
Research and Development by Bishnu Adhikari
The document discusses the key steps involved in research and development of new medicines. It involves several years of pre-clinical and clinical testing to determine safety, efficacy, appropriate dosage form and marketing strategy. The process includes discovery of new compounds, laboratory and animal testing to determine toxicity and pharmacokinetics, followed by three phases of human clinical trials of increasing sample size. In parallel, development activities such as formulation, manufacturing, packaging and regulatory approval are also undertaken to commercialize the new medicine if clinical trials are successful. The overall process typically takes 12-15 years to develop a new medicine from initial research to market availability.
Harmonization of Approaches for Food Ingredients and Constituents: Is It Poss...
Harmonization of Approaches for Food Ingredients and Constituents: Is It Poss...Burdock Group Consultants
Presented by Dr. Ray Matulka at IFT15 on Sunday, July 12 at 1:15 PM.
The basic principles of safety can apply to all constituents in foods and beverages whether they are present purposefully or not. However, numerous factors can influence the approaches utilized for hazard characterization and risk assessment for various food and beverage constituents. These factors can include; the regulatory and legal framework being followed, what is and what is not known scientifically about the safety of a constituent, what the substance is and its function in a food or beverage, and consumer perception of the substance in the food or beverage. Simply segregating the safety assessment of compounds found in foods and beverages based how they came to be present in foods and beverages can be problematic for all stakeholders charged with ensuring the safety of foods and beverages. Additionally, food safety organizations around the world have adopted a variety of different approaches for addressing the safety of constituents in foods and beverages, which complicates, rather than simplifies the risk assessment process. The ability to adopt and adapt various scientifically valid approaches for evaluating safety becomes important for ensuring the safety and continuity of supply of foods and beverages. Another important factor that must be considered while evaluating the safety of constituents in food and beverages is communication with the consumer and crafting appropriate messaging demonstrating the rigor of the evaluation with a goal of preserving and promoting trust in the safety of the food and beverage supply.Vitargent introduction20130507
Vitargent is a Hong Kong-based biotechnology company that provides testing services and products to assess the impact of estrogenic chemicals and other pollutants. It has established several reference cases working with cosmetics companies and testing labs. Vitargent launched an "estrogen safe mark" and obtained accreditation making it the only lab in Asia that can provide certain toxicity testing. It is seeking strategic partners to help promote its programs, develop testing standards, and potentially pursue an IPO. Vitargent's services and products assess chemicals/pollutants like dioxins and it utilizes transgenic fish models to detect estrogenic substances in products like food, drugs, and the environment.
Petzold Et Al.docx
The document discusses implementing the Opioid Risk Screening Tool (ORT) in a primary care clinic over 8-10 weeks. The ORT will be used to improve identification and referral of chronic pain patients to a pain clinic. The implementation will be guided by the Knowledge to Action theory and involve educating staff on using the ORT. Patients will complete the ORT during visits, nurses will score it, and providers will discuss results. Initial implementation has involved occasional missed administration of the ORT, but it is progressing as the team adjusts to the new process.
Plain Language Summary Roadshow
This document provides an overview of plain language summaries (PLS) and a company's PLS program. It defines a PLS as a scientifically accurate, non-promotional translation of clinical trial results into easy-to-understand language. The document discusses the importance of sharing results with trial participants and investigators based on feedback from studies. It also reviews regulatory requirements for posting PLS, such as the EU Clinical Trials Regulation requiring posting within 1 year of study completion. Finally, it states that the company's PLS program information will be inserted to describe how it will implement PLS within timelines and any pilot studies.
Quality and Regulatory Affairs
The document discusses the regulatory IND (Investigational New Drug) process for bringing a new drug to market in the United States. It outlines the requirements for submitting an IND application to the FDA, including non-clinical data from animal and early human studies demonstrating safety and effectiveness. Key components that must be addressed are chemistry and manufacturing controls, pharmacology and toxicology data, clinical protocols, and plans for interaction and meetings with FDA regulators during the process.
Continuous Decision Improvement: Decisive Leadership for Complex Environments
This document outlines the concept of Continuous Decision Improvement (CDI) as presented by Tomas J. Aragon. It discusses CDI as a process for public health leaders to continuously improve their decision making in complex environments. The 4D Decision Process is presented as a framework for rational decision making, involving defining problems, designing alternatives, deciding on alternatives, and implementing solutions. CDI then builds on this by incorporating elements of quality improvement to continuously refine and enhance the decision making process. Examples of applying CDI to specific public health decisions are also provided.
Praveen Balimane Addresses SLAS ADMET Special Interest Group at SLAS2015
Praveen Balimane Addresses SLAS ADMET Special Interest Group at SLAS2015SLAS (Society for Laboratory Automation and Screening)
Dr. Praveen Balimane, senior staff fellow, Division of Clinical Pharmacology-1 at OCP/OTS/CDER/FDA, spoke during the Society for Laboratory Automation and Screening ADMET Special Interest Group Meeting on “Transporter Evaluation in Drug Development.”
Transporters, like CYPs, are being recognized as proteins that can play a pivotal role in dictating the ADME properties of drugs. A thorough understanding of potential roles of transporters in drug interactions and toxicity is important in drug development. The talk provided a high level overview of various transporter evaluation initiatives at the agency. Some of the topics discussed:
• On-going efforts on decision trees within the DDI guidance
• Novel emerging transporters impacting ADME
• Inter-play of hepatic transporters and liver-toxicity
• Inter-play of renal transporters and renal functionPharmaceutical Quality - The Office of
The keynote address at the Fall meeting of the CPPR Industrial Advisory Board and the Site Directors held yesterday (27 October 2014) at Purdue University. The talk provides a perspective on the recent organizational changes announced by FDA CDER - the Office of Pharmaceutical Quality.
2013-04-17 Pharma-Nutrition Singapore
Pharma-Nutrition: a pharma perspective. View how the pharmaceutical drug development model can and should be combined with the nutrition field to optimally implement personalized healthcare.
CAVERSTEM Corporate Presentation
A regenerative medicine company is developing a patented stem cell therapy using a patient's own stem cells to treat erectile dysfunction. The therapy involves extracting stem cells from the patient's penis through a minimally invasive procedure. Animal research and a human case study showed improved erectile function. A clinical trial at UCLA is underway to establish the therapy as the standard of care. The company aims to be the first to market in 2017 with a full package offering of protocol, clinical trial results, devices, and training to urologists.
2015 10-06 Building Bridges Biomarker symposium FIMM Helsinki, Alain van Gool
A unique honour and opportunity to give a 1.5 hour lecture to young biomarker scientists to introduce biomarkers and their importance in translational medicine and personalized healthcare.
Options for Medical Students to Follow: The Biomedical Industries Pathway
Vasilios Papademetriou is a cardiologist and professor of medicine at Georgetown University who has collaborated extensively with the biomedical industry. He discusses several career pathways for medical students in the biomedical industry, including doing clinical trials sponsored by industry, serving on advisory boards, and collaborating on research. He provides examples of physicians who have successfully worked with industry to develop new drugs and devices.
KTIS Webinar 3: Who needs to do what, differently, to promote implementation?
KTIS Webinar 3: Who needs to do what, differently, to promote implementation? Canadian Patient Safety Institute
The third interactive webinar in the series builds on the second session by focusing on the question: once we have evidence to justify implementing a new patient safety initiative, what next? Careers In Clinical Research 2009
1. Dr. Ashok Rattan has over 30 years of experience in clinical research and drug development, currently serving as Chief Executive of Fortis Clinical Research and Adviser to Religare SRL Diagnostics and Fortis/Escorts Hospitals.
2. Bringing a new drug to market typically takes 15 years and over $800 million, going through pre-clinical testing, 3 phases of clinical trials, and regulatory review and approval.
3. There is a large demand and supply gap for professionals in clinical research in India, with opportunities in areas like project management, data management, medical writing, and regulatory affairs.
Clinical study and gcp
Clinical trials progress through phases (preclinical, I-IV) to evaluate treatments safely in humans. Preclinical testing occurs in labs and animals. Phase I studies evaluate safety in 20-80 healthy volunteers. Phase II expands to 100-300 patient volunteers to assess efficacy. Phase III further tests efficacy in 1,000-3,000 patients. FDA approval requires compliance with Good Clinical Practice guidelines to protect subject rights and ensure credible data. Key elements include oversight by independent review boards, informed consent, qualified investigators and sponsors, adherence to protocols, and comprehensive record keeping.
SMi Group's 9th annual ADMET conference & exhibition
This document provides information about the 9th annual conference on ADMET (Absorption, Distribution, Metabolism, Excretion and Toxicity) enhancing drug quality by ADMET optimisation in discovery that will take place from June 30th to July 2nd 2014 at the Marriott Regents Park Hotel in London. Key information includes:
- Discounts are available for booking by March 31st (save £300) and April 30th (save £100).
- The conference will focus on integrating ADMET and toxicity data to enhance drug safety prediction, drug transporters, predictive toxicology, and computational/in vitro ADMET approaches.
- There will be presentations from industry leaders at companies like
Effective management of surgical instruments
This presentation give information how important cleaning process in hospital to reduce cost stay in hospital and increase hospital revenue
Key Considerations in Stability Studies for Biopharmaceuticals
Conducting stability studies in accordance with regulatory requirements requires technical expertise, established infrastructure and compliant facilities. There are multiple contractors available to offer these services and often the selection of a lead contractor is based on top level quotes and business development feedback. However, based on such selection strategies, once the studies are established at a contract site, additional factors may arise that further impact the overall costs and timelines for your project. These include hidden costs due to factors such as data mining, trending and investigations required during an established study.
Factors that affect timelines include flexibility required to ensure relevant data is available as required for key submission dates. If this is not the case, this will result in reduced shelf life assignment and may have a direct impact on product development timeline.
This talk will look at key points to consider in the selection process and provide tools to aid in selection of a lead contractor.
Rm profile robust_analytical and consultancy service_v2_092017
Robust Materials Technology Pvt. Ltd. is an integrated solutions provider for the pharmaceutical, food, environmental, and chemical industries with facilities in Bangalore, India and Atlanta, USA. The company offers analytical services, quality control, regulatory support, product R&D, facility establishment, and training. Robust has numerous national and international approvals and its infrastructure includes wet chemistry, instrumentation, and microbiology laboratories staffed by experts. The document provides details on Robust's services, accreditations, unique projects, and contact information.
Resume 1
Martin A. Derusha Jr. has over 25 years of experience in various roles including physician, consultant, developer, researcher, and crew chief. He has worked in the US and India in healthcare, oil and gas, construction, academia, and irrigation. His background includes emergency medicine, family practice, pharmacology research, and building a 30-bed hospital in India. He has skills in areas such as critical thinking, science, foreign languages, and time management.
Changing Behaviour in the Operating Theatre - GlobalSurg Implementation prese...
Changing Behaviour in the Operating Theatre - GlobalSurg Implementation prese...Dr Edward Fitzgerald
Changing Behaviour in the Operating Theatre - GlobalSurg Implementation presentation for global surgery planning meeting in South AfricaSocial values international programme: integrating research and policy to ens...
Social values international programme: integrating research and policy to ensure fair allocation of health care resources .
HTAi Conference 2012 Panel Session
Joint chairs
Professor Peter Littlejohns and Professor Albert Weale
connectors in FPD.pptx
The document discusses connectors in fixed partial dentures. Connectors are defined as the portion of a fixed dental prosthesis that unites the retainers and pontics. Connectors must be sufficiently strong, elliptical in cross-section, and placed as lingually and incisally as possible in anterior teeth and in the occlusal third for posterior teeth. Rigid connectors include cast, soldered, and loop connectors while non-rigid connectors allow limited movement and include dovetail, split, and cross-pin connectors. Soldering techniques such as torch, oven, laser, and infrared soldering are described for joining connectors along with considerations for solder composition and properties.
tooth prep PUTTARAJ TK.ppt
This document discusses principles of tooth preparation for prosthodontic treatment. It defines tooth preparation as mechanical treatment of hard dental tissues to restore a tooth to its original form. The key principles discussed are preservation of tooth structure, achieving retention and resistance form, and maintaining structural durability and marginal integrity of restorations. Factors that influence retention and resistance form, such as taper, surface area, and path of insertion are also examined.
More Related Content
Similar to biocompatabity.ppt
Petzold Et Al.docx
The document discusses implementing the Opioid Risk Screening Tool (ORT) in a primary care clinic over 8-10 weeks. The ORT will be used to improve identification and referral of chronic pain patients to a pain clinic. The implementation will be guided by the Knowledge to Action theory and involve educating staff on using the ORT. Patients will complete the ORT during visits, nurses will score it, and providers will discuss results. Initial implementation has involved occasional missed administration of the ORT, but it is progressing as the team adjusts to the new process.
Plain Language Summary Roadshow
This document provides an overview of plain language summaries (PLS) and a company's PLS program. It defines a PLS as a scientifically accurate, non-promotional translation of clinical trial results into easy-to-understand language. The document discusses the importance of sharing results with trial participants and investigators based on feedback from studies. It also reviews regulatory requirements for posting PLS, such as the EU Clinical Trials Regulation requiring posting within 1 year of study completion. Finally, it states that the company's PLS program information will be inserted to describe how it will implement PLS within timelines and any pilot studies.
Quality and Regulatory Affairs
The document discusses the regulatory IND (Investigational New Drug) process for bringing a new drug to market in the United States. It outlines the requirements for submitting an IND application to the FDA, including non-clinical data from animal and early human studies demonstrating safety and effectiveness. Key components that must be addressed are chemistry and manufacturing controls, pharmacology and toxicology data, clinical protocols, and plans for interaction and meetings with FDA regulators during the process.
Continuous Decision Improvement: Decisive Leadership for Complex Environments
This document outlines the concept of Continuous Decision Improvement (CDI) as presented by Tomas J. Aragon. It discusses CDI as a process for public health leaders to continuously improve their decision making in complex environments. The 4D Decision Process is presented as a framework for rational decision making, involving defining problems, designing alternatives, deciding on alternatives, and implementing solutions. CDI then builds on this by incorporating elements of quality improvement to continuously refine and enhance the decision making process. Examples of applying CDI to specific public health decisions are also provided.
Praveen Balimane Addresses SLAS ADMET Special Interest Group at SLAS2015
Praveen Balimane Addresses SLAS ADMET Special Interest Group at SLAS2015SLAS (Society for Laboratory Automation and Screening)
Dr. Praveen Balimane, senior staff fellow, Division of Clinical Pharmacology-1 at OCP/OTS/CDER/FDA, spoke during the Society for Laboratory Automation and Screening ADMET Special Interest Group Meeting on “Transporter Evaluation in Drug Development.”
Transporters, like CYPs, are being recognized as proteins that can play a pivotal role in dictating the ADME properties of drugs. A thorough understanding of potential roles of transporters in drug interactions and toxicity is important in drug development. The talk provided a high level overview of various transporter evaluation initiatives at the agency. Some of the topics discussed:
• On-going efforts on decision trees within the DDI guidance
• Novel emerging transporters impacting ADME
• Inter-play of hepatic transporters and liver-toxicity
• Inter-play of renal transporters and renal functionPharmaceutical Quality - The Office of
The keynote address at the Fall meeting of the CPPR Industrial Advisory Board and the Site Directors held yesterday (27 October 2014) at Purdue University. The talk provides a perspective on the recent organizational changes announced by FDA CDER - the Office of Pharmaceutical Quality.
2013-04-17 Pharma-Nutrition Singapore
Pharma-Nutrition: a pharma perspective. View how the pharmaceutical drug development model can and should be combined with the nutrition field to optimally implement personalized healthcare.
CAVERSTEM Corporate Presentation
A regenerative medicine company is developing a patented stem cell therapy using a patient's own stem cells to treat erectile dysfunction. The therapy involves extracting stem cells from the patient's penis through a minimally invasive procedure. Animal research and a human case study showed improved erectile function. A clinical trial at UCLA is underway to establish the therapy as the standard of care. The company aims to be the first to market in 2017 with a full package offering of protocol, clinical trial results, devices, and training to urologists.
2015 10-06 Building Bridges Biomarker symposium FIMM Helsinki, Alain van Gool
A unique honour and opportunity to give a 1.5 hour lecture to young biomarker scientists to introduce biomarkers and their importance in translational medicine and personalized healthcare.
Options for Medical Students to Follow: The Biomedical Industries Pathway
Vasilios Papademetriou is a cardiologist and professor of medicine at Georgetown University who has collaborated extensively with the biomedical industry. He discusses several career pathways for medical students in the biomedical industry, including doing clinical trials sponsored by industry, serving on advisory boards, and collaborating on research. He provides examples of physicians who have successfully worked with industry to develop new drugs and devices.
KTIS Webinar 3: Who needs to do what, differently, to promote implementation?
KTIS Webinar 3: Who needs to do what, differently, to promote implementation? Canadian Patient Safety Institute
The third interactive webinar in the series builds on the second session by focusing on the question: once we have evidence to justify implementing a new patient safety initiative, what next? Careers In Clinical Research 2009
1. Dr. Ashok Rattan has over 30 years of experience in clinical research and drug development, currently serving as Chief Executive of Fortis Clinical Research and Adviser to Religare SRL Diagnostics and Fortis/Escorts Hospitals.
2. Bringing a new drug to market typically takes 15 years and over $800 million, going through pre-clinical testing, 3 phases of clinical trials, and regulatory review and approval.
3. There is a large demand and supply gap for professionals in clinical research in India, with opportunities in areas like project management, data management, medical writing, and regulatory affairs.
Clinical study and gcp
Clinical trials progress through phases (preclinical, I-IV) to evaluate treatments safely in humans. Preclinical testing occurs in labs and animals. Phase I studies evaluate safety in 20-80 healthy volunteers. Phase II expands to 100-300 patient volunteers to assess efficacy. Phase III further tests efficacy in 1,000-3,000 patients. FDA approval requires compliance with Good Clinical Practice guidelines to protect subject rights and ensure credible data. Key elements include oversight by independent review boards, informed consent, qualified investigators and sponsors, adherence to protocols, and comprehensive record keeping.
SMi Group's 9th annual ADMET conference & exhibition
This document provides information about the 9th annual conference on ADMET (Absorption, Distribution, Metabolism, Excretion and Toxicity) enhancing drug quality by ADMET optimisation in discovery that will take place from June 30th to July 2nd 2014 at the Marriott Regents Park Hotel in London. Key information includes:
- Discounts are available for booking by March 31st (save £300) and April 30th (save £100).
- The conference will focus on integrating ADMET and toxicity data to enhance drug safety prediction, drug transporters, predictive toxicology, and computational/in vitro ADMET approaches.
- There will be presentations from industry leaders at companies like
Effective management of surgical instruments
This presentation give information how important cleaning process in hospital to reduce cost stay in hospital and increase hospital revenue
Key Considerations in Stability Studies for Biopharmaceuticals
Conducting stability studies in accordance with regulatory requirements requires technical expertise, established infrastructure and compliant facilities. There are multiple contractors available to offer these services and often the selection of a lead contractor is based on top level quotes and business development feedback. However, based on such selection strategies, once the studies are established at a contract site, additional factors may arise that further impact the overall costs and timelines for your project. These include hidden costs due to factors such as data mining, trending and investigations required during an established study.
Factors that affect timelines include flexibility required to ensure relevant data is available as required for key submission dates. If this is not the case, this will result in reduced shelf life assignment and may have a direct impact on product development timeline.
This talk will look at key points to consider in the selection process and provide tools to aid in selection of a lead contractor.
Rm profile robust_analytical and consultancy service_v2_092017
Robust Materials Technology Pvt. Ltd. is an integrated solutions provider for the pharmaceutical, food, environmental, and chemical industries with facilities in Bangalore, India and Atlanta, USA. The company offers analytical services, quality control, regulatory support, product R&D, facility establishment, and training. Robust has numerous national and international approvals and its infrastructure includes wet chemistry, instrumentation, and microbiology laboratories staffed by experts. The document provides details on Robust's services, accreditations, unique projects, and contact information.
Resume 1
Martin A. Derusha Jr. has over 25 years of experience in various roles including physician, consultant, developer, researcher, and crew chief. He has worked in the US and India in healthcare, oil and gas, construction, academia, and irrigation. His background includes emergency medicine, family practice, pharmacology research, and building a 30-bed hospital in India. He has skills in areas such as critical thinking, science, foreign languages, and time management.
Changing Behaviour in the Operating Theatre - GlobalSurg Implementation prese...
Changing Behaviour in the Operating Theatre - GlobalSurg Implementation prese...Dr Edward Fitzgerald
Changing Behaviour in the Operating Theatre - GlobalSurg Implementation presentation for global surgery planning meeting in South AfricaSocial values international programme: integrating research and policy to ens...
Social values international programme: integrating research and policy to ensure fair allocation of health care resources .
HTAi Conference 2012 Panel Session
Joint chairs
Professor Peter Littlejohns and Professor Albert Weale
Similar to biocompatabity.ppt (20)
Continuous Decision Improvement: Decisive Leadership for Complex Environments
Continuous Decision Improvement: Decisive Leadership for Complex Environments
Praveen Balimane Addresses SLAS ADMET Special Interest Group at SLAS2015
Praveen Balimane Addresses SLAS ADMET Special Interest Group at SLAS2015
2015 10-06 Building Bridges Biomarker symposium FIMM Helsinki, Alain van Gool
2015 10-06 Building Bridges Biomarker symposium FIMM Helsinki, Alain van Gool
Options for Medical Students to Follow: The Biomedical Industries Pathway
Options for Medical Students to Follow: The Biomedical Industries Pathway
KTIS Webinar 3: Who needs to do what, differently, to promote implementation?
KTIS Webinar 3: Who needs to do what, differently, to promote implementation?
SMi Group's 9th annual ADMET conference & exhibition
SMi Group's 9th annual ADMET conference & exhibition
Key Considerations in Stability Studies for Biopharmaceuticals
Key Considerations in Stability Studies for Biopharmaceuticals
Rm profile robust_analytical and consultancy service_v2_092017
Rm profile robust_analytical and consultancy service_v2_092017
Changing Behaviour in the Operating Theatre - GlobalSurg Implementation prese...
Changing Behaviour in the Operating Theatre - GlobalSurg Implementation prese...
Social values international programme: integrating research and policy to ens...
Social values international programme: integrating research and policy to ens...
More from Dr. Puttaraj TK
connectors in FPD.pptx
The document discusses connectors in fixed partial dentures. Connectors are defined as the portion of a fixed dental prosthesis that unites the retainers and pontics. Connectors must be sufficiently strong, elliptical in cross-section, and placed as lingually and incisally as possible in anterior teeth and in the occlusal third for posterior teeth. Rigid connectors include cast, soldered, and loop connectors while non-rigid connectors allow limited movement and include dovetail, split, and cross-pin connectors. Soldering techniques such as torch, oven, laser, and infrared soldering are described for joining connectors along with considerations for solder composition and properties.
tooth prep PUTTARAJ TK.ppt
This document discusses principles of tooth preparation for prosthodontic treatment. It defines tooth preparation as mechanical treatment of hard dental tissues to restore a tooth to its original form. The key principles discussed are preservation of tooth structure, achieving retention and resistance form, and maintaining structural durability and marginal integrity of restorations. Factors that influence retention and resistance form, such as taper, surface area, and path of insertion are also examined.
DENTAL CERAMICS (2).ppt
This document provides an overview of dental ceramics, including their composition, classification, structure, manufacturing process, and bonding to metal. It discusses the main components of dental ceramics such as feldspar, quartz, alumina, and kaolin. It classifies ceramics according to their microstructure, firing temperature, use, and composition. Key steps in the manufacturing process include fritting, porcelain condensation, sintering, and firing. The bonding of porcelain to metal involves mechanical, compressive, and chemical bonding. Methods to strengthen ceramics include minimizing stress concentrators, developing residual compressive stresses, and ion exchange.
biocompatabity.ppt
The document discusses the biocompatibility of dental materials. It defines biocompatibility as materials being harmonious with life and not having toxic or injurious effects on biologic functions. Any material used in the body for any period of time to treat, augment or replace tissue or organs is considered a biomaterial. Standards for evaluating biocompatibility include primary, secondary and usage tests. Ensuring biocompatibility of dental materials is important for preventing adverse reactions like allergic responses.
teeth selection for CD.pptx
Teeth selection for complete dentures involves considering several factors to ensure function and aesthetics. Size is based on facial measurements and residual ridge contours. Form depends on facial profile, sex, age and personality. Color should harmonize with complexion. Anterior teeth material is typically porcelain or acrylic. Posterior teeth shade matches anterior teeth and form depends on occlusion type. Anatomic teeth are more aesthetic but non-anatomic teeth are more comfortable in resorbed ridges. Proper teeth selection improves denture function and patient confidence.
abrasives polishing agents.pptx
The document discusses abrasives and polishing agents used in dentistry. It describes the benefits of finishing and polishing dental restorations, including promoting oral hygiene, enhancing oral function, and improving esthetics. It also defines abrasion and different types of abrasives, including natural and manufactured abrasives. The document outlines different techniques for finishing and polishing, including using abrasive grits, bonded abrasives, coated abrasive disks and strips, as well as non-abrasive polishing methods. Recent advancements in polishing techniques are also mentioned.
spl imp tech.pptx
This document discusses various techniques for making impressions for removable partial dentures with distal extensions, including:
1. McLean's technique and Hindel's technique, which are physiologic impression methods that involve making an initial impression under finger pressure and a secondary impression.
2. The functional relining technique, which involves adding new material to the inner side of an existing denture base to improve fit after bone resorption.
3. The fluid wax technique, which uses a wax that flows at mouth temperature to record tissue contours over time as the impression is seated.
4. The selective pressure technique, which uses different impression materials and visual determination of complete seating to record areas under and not under pressure.
COMLETE DENUTRE CASE HISTORY.ppt
The document provides guidance on taking a case history for a completely edentulous patient. It outlines the importance of collecting personal data like name, age, sex, address, occupation, chief complaint, medical history, dental history, and psychosocial status. A thorough case history helps the dentist arrive at a probable diagnosis and treatment plan that considers the patient's general health, lifestyle factors, and expectations.
THESIS OUTLINE.pptx
This document provides guidelines for writing a thesis or dissertation. It discusses defining research and the difference between a thesis and dissertation. Key parts of a thesis are described such as the introduction, literature review, materials and methods, results, discussion, and conclusion sections. The document emphasizes following university guidelines and formatting standards. It also provides advice on choosing a topic, conducting research, acknowledging help, and submitting the final thesis. Overall, the document serves as a comprehensive guide outlining the essential components and process for writing a successful thesis or dissertation.
4- Gingival Retraction & Impressions.ppt
This document discusses gingival retraction and impression making techniques. It describes gingival retraction as deflecting or displacing the gingiva from the tooth to record the margins. Various gingival retraction methods are covered, including mechanical retraction cords, electrosurgery, and newer cordless techniques using materials like Expasyl and Magic Foam. Key steps for making good impressions are also outlined, such as selecting the proper tray and impression material and evaluating the resulting impression. The conclusion emphasizes choosing a gingival retraction method suited to the clinical situation while prioritizing tissue health and patient comfort.
More from Dr. Puttaraj TK (10)
Recently uploaded
REGULATION FOR COMBINATION PRODUCTS AND MEDICAL DEVICES.pptx
It includes regulation of combination products and medical devices. FDA and industry liaisons.
Ketone bodies and metabolism-biochemistry
This slide consists of all the topics of ketone . This can be used for exam purpose for writing about Diabetic keto acidosis etc . Thank you
Osteoporosis - Definition , Evaluation and Management .pdf
Osteoporosis is an increasing cause of morbidity among the elderly.
In this document , a brief outline of osteoporosis is given , including the risk factors of osteoporosis fractures , the indications for testing bone mineral density and the management of osteoporosis
Role of Mukta Pishti in the Management of Hyperthyroidism
Muktapishti is a traditional Ayurvedic preparation made from Shoditha Mukta (Purified Pearl), is believed to help regulate thyroid function and reduce symptoms of hyperthyroidism due to its cooling and balancing properties. Clinical evidence on its efficacy remains limited, necessitating further research to validate its therapeutic benefits.
Integrating Ayurveda into Parkinson’s Management: A Holistic Approach
Explore the benefits of combining Ayurveda with conventional Parkinson's treatments. Learn how a holistic approach can manage symptoms, enhance well-being, and balance body energies. Discover the steps to safely integrate Ayurvedic practices into your Parkinson’s care plan, including expert guidance on diet, herbal remedies, and lifestyle modifications.
Histololgy of Female Reproductive System.pptx
Dive into an in-depth exploration of the histological structure of female reproductive system with this comprehensive lecture. Presented by Dr. Ayesha Irfan, Assistant Professor of Anatomy, this presentation covers the Gross anatomy and functional histology of the female reproductive organs. Ideal for students, educators, and anyone interested in medical science, this lecture provides clear explanations, detailed diagrams, and valuable insights into female reproductive system. Enhance your knowledge and understanding of this essential aspect of human biology.
Cell Therapy Expansion and Challenges in Autoimmune Disease
There is increasing confidence that cell therapies will soon play a role in the treatment of autoimmune disorders, but the extent of this impact remains to be seen. Early readouts on autologous CAR-Ts in lupus are encouraging, but manufacturing and cost limitations are likely to restrict access to highly refractory patients. Allogeneic CAR-Ts have the potential to broaden access to earlier lines of treatment due to their inherent cost benefits, however they will need to demonstrate comparable or improved efficacy to established modalities.
In addition to infrastructure and capacity constraints, CAR-Ts face a very different risk-benefit dynamic in autoimmune compared to oncology, highlighting the need for tolerable therapies with low adverse event risk. CAR-NK and Treg-based therapies are also being developed in certain autoimmune disorders and may demonstrate favorable safety profiles. Several novel non-cell therapies such as bispecific antibodies, nanobodies, and RNAi drugs, may also offer future alternative competitive solutions with variable value propositions.
Widespread adoption of cell therapies will not only require strong efficacy and safety data, but also adapted pricing and access strategies. At oncology-based price points, CAR-Ts are unlikely to achieve broad market access in autoimmune disorders, with eligible patient populations that are potentially orders of magnitude greater than the number of currently addressable cancer patients. Developers have made strides towards reducing cell therapy COGS while improving manufacturing efficiency, but payors will inevitably restrict access until more sustainable pricing is achieved.
Despite these headwinds, industry leaders and investors remain confident that cell therapies are poised to address significant unmet need in patients suffering from autoimmune disorders. However, the extent of this impact on the treatment landscape remains to be seen, as the industry rapidly approaches an inflection point.
A Classical Text Review on Basavarajeeyam
Basavarajeeyam is a Sreshta Sangraha grantha (Compiled book ), written by Neelkanta kotturu Basavaraja Virachita. It contains 25 Prakaranas, First 24 Chapters related to Rogas& 25th to Rasadravyas.
Part II - Body Grief: Losing parts of ourselves and our identity before, duri...
Learn about body grief and ways to cope with it. We will also explore methods to heal from this challenging experience.
Hemodialysis: Chapter 4, Dialysate Circuit - Dr.Gawad
- Video recording of this lecture in English language: https://youtu.be/kqbnxVAZs-0
- Video recording of this lecture in Arabic language: https://youtu.be/SINlygW1Mpc
- Link to download the book free: https://nephrotube.blogspot.com/p/nephrotube-nephrology-books.html
- Link to NephroTube website: www.NephroTube.com
- Link to NephroTube social media accounts: https://nephrotube.blogspot.com/p/join-nephrotube-on-social-media.html
TEST BANK For Community Health Nursing A Canadian Perspective, 5th Edition by...
TEST BANK For Community Health Nursing A Canadian Perspective, 5th Edition by Stamler, Verified Chapters 1 - 33, Complete Newest Version Community Health Nursing A Canadian Perspective, 5th Edition by Stamler, Verified Chapters 1 - 33, Complete Newest Version Community Health Nursing A Canadian Perspective, 5th Edition by Stamler Community Health Nursing A Canadian Perspective, 5th Edition TEST BANK by Stamler Test Bank For Community Health Nursing A Canadian Perspective, 5th Edition Pdf Chapters Download Test Bank For Community Health Nursing A Canadian Perspective, 5th Edition Pdf Download Stuvia Test Bank For Community Health Nursing A Canadian Perspective, 5th Edition Study Guide Test Bank For Community Health Nursing A Canadian Perspective, 5th Edition Ebook Download Stuvia Test Bank For Community Health Nursing A Canadian Perspective, 5th Edition Questions and Answers Quizlet Test Bank For Community Health Nursing A Canadian Perspective, 5th Edition Studocu Test Bank For Community Health Nursing A Canadian Perspective, 5th Edition Quizlet Test Bank For Community Health Nursing A Canadian Perspective, 5th Edition Stuvia Community Health Nursing A Canadian Perspective, 5th Edition Pdf Chapters Download Community Health Nursing A Canadian Perspective, 5th Edition Pdf Download Course Hero Community Health Nursing A Canadian Perspective, 5th Edition Answers Quizlet Community Health Nursing A Canadian Perspective, 5th Edition Ebook Download Course hero Community Health Nursing A Canadian Perspective, 5th Edition Questions and Answers Community Health Nursing A Canadian Perspective, 5th Edition Studocu Community Health Nursing A Canadian Perspective, 5th Edition Quizlet Community Health Nursing A Canadian Perspective, 5th Edition Stuvia Community Health Nursing A Canadian Perspective, 5th Edition Test Bank Pdf Chapters Download Community Health Nursing A Canadian Perspective, 5th Edition Test Bank Pdf Download Stuvia Community Health Nursing A Canadian Perspective, 5th Edition Test Bank Study Guide Questions and Answers Community Health Nursing A Canadian Perspective, 5th Edition Test Bank Ebook Download Stuvia Community Health Nursing A Canadian Perspective, 5th Edition Test Bank Questions Quizlet Community Health Nursing A Canadian Perspective, 5th Edition Test Bank Studocu Community Health Nursing A Canadian Perspective, 5th Edition Test Bank Quizlet Community Health Nursing A Canadian Perspective, 5th Edition Test Bank Stuvia
Adhd Medication Shortage Uk - trinexpharmacy.com
The UK is currently facing a Adhd Medication Shortage Uk, which has left many patients and their families grappling with uncertainty and frustration. ADHD, or Attention Deficit Hyperactivity Disorder, is a chronic condition that requires consistent medication to manage effectively. This shortage has highlighted the critical role these medications play in the daily lives of those affected by ADHD. Contact : +1 (747) 209 – 3649 E-mail : sales@trinexpharmacy.com
Clinic ^%[+27633867063*Abortion Pills For Sale In Tembisa Central
Clinic ^%[+27633867063*Abortion Pills For Sale In Tembisa Central Clinic ^%[+27633867063*Abortion Pills For Sale In Tembisa CentralClinic ^%[+27633867063*Abortion Pills For Sale In Tembisa CentralClinic ^%[+27633867063*Abortion Pills For Sale In Tembisa CentralClinic ^%[+27633867063*Abortion Pills For Sale In Tembisa Central
TEST BANK For An Introduction to Brain and Behavior, 7th Edition by Bryan Kol...
TEST BANK For An Introduction to Brain and Behavior, 7th Edition by Bryan Kol...rightmanforbloodline
TEST BANK For An Introduction to Brain and Behavior, 7th Edition by Bryan Kolb, Ian Q. Whishaw, Verified Chapters 1 - 16, Complete Newest Versio
TEST BANK For An Introduction to Brain and Behavior, 7th Edition by Bryan Kolb, Ian Q. Whishaw, Verified Chapters 1 - 16, Complete Newest Version
TEST BANK For An Introduction to Brain and Behavior, 7th Edition by Bryan Kolb, Ian Q. Whishaw, Verified Chapters 1 - 16, Complete Newest VersionTop-Vitamin-Supplement-Brands-in-India List
Swisschem Dermacare provides the Top 10 Vitamin Supplement Brands in India. To know more about us give us call at our official number
8 Surprising Reasons To Meditate 40 Minutes A Day That Can Change Your Life.pptx
8 Surprising Reasons To Meditate 40 Minutes A Day That Can Change Your Life.pptxHolistified Wellness
We’re talking about Vedic Meditation, a form of meditation that has been around for at least 5,000 years. Back then, the people who lived in the Indus Valley, now known as India and Pakistan, practised meditation as a fundamental part of daily life. This knowledge that has given us yoga and Ayurveda, was known as Veda, hence the name Vedic. And though there are some written records, the practice has been passed down verbally from generation to generation.Top 10 Best Ayurvedic Kidney Stone Syrups in India
we have mentioned the best 10 ayurvedic Kidney Stone Syrups. You can check all these products and choose the best one for yourself.
share - Lions, tigers, AI and health misinformation, oh my!.pptx
• Pitfalls and pivots needed to use AI effectively in public health
• Evidence-based strategies to address health misinformation effectively
• Building trust with communities online and offline
• Equipping health professionals to address questions, concerns and health misinformation
• Assessing risk and mitigating harm from adverse health narratives in communities, health workforce and health system
Recently uploaded (20)
REGULATION FOR COMBINATION PRODUCTS AND MEDICAL DEVICES.pptx
REGULATION FOR COMBINATION PRODUCTS AND MEDICAL DEVICES.pptx
Osteoporosis - Definition , Evaluation and Management .pdf
Osteoporosis - Definition , Evaluation and Management .pdf
Role of Mukta Pishti in the Management of Hyperthyroidism
Role of Mukta Pishti in the Management of Hyperthyroidism
Integrating Ayurveda into Parkinson’s Management: A Holistic Approach
Integrating Ayurveda into Parkinson’s Management: A Holistic Approach
Cell Therapy Expansion and Challenges in Autoimmune Disease
Cell Therapy Expansion and Challenges in Autoimmune Disease
Part II - Body Grief: Losing parts of ourselves and our identity before, duri...
Part II - Body Grief: Losing parts of ourselves and our identity before, duri...
Hemodialysis: Chapter 4, Dialysate Circuit - Dr.Gawad
Hemodialysis: Chapter 4, Dialysate Circuit - Dr.Gawad
TEST BANK For Community Health Nursing A Canadian Perspective, 5th Edition by...
TEST BANK For Community Health Nursing A Canadian Perspective, 5th Edition by...
Clinic ^%[+27633867063*Abortion Pills For Sale In Tembisa Central
Clinic ^%[+27633867063*Abortion Pills For Sale In Tembisa Central
TEST BANK For An Introduction to Brain and Behavior, 7th Edition by Bryan Kol...
TEST BANK For An Introduction to Brain and Behavior, 7th Edition by Bryan Kol...
8 Surprising Reasons To Meditate 40 Minutes A Day That Can Change Your Life.pptx
8 Surprising Reasons To Meditate 40 Minutes A Day That Can Change Your Life.pptx
Top 10 Best Ayurvedic Kidney Stone Syrups in India
Top 10 Best Ayurvedic Kidney Stone Syrups in India
share - Lions, tigers, AI and health misinformation, oh my!.pptx
share - Lions, tigers, AI and health misinformation, oh my!.pptx
biocompatabity.ppt
- 1. BIOCOMPATIBILITY OF DENTAL MATERIALS BY DR PUTTARAJ.T.K. Prof.& H.O.D. Dept of Prosthodontics & D.M. 1
- 2. 10.Keys for successful student life • Analytical skills and communication • Flexibility • Decisiveness • Creativity • Risk taking activity • Stress tolerance • Perseverance • Organizing capabilities • Leadership • Great interest and attitude of openness
- 4. 17-10-2015
- 5. 17-10-2015
- 7. 17-10-2015 Being harmonious with life & not having toxic or injurious effects on biologic function.(G.P.T. 8th edn.-2005)
- 8. 17-10-2015
- 9. 17-10-2015 Any substance, other than a drug, that can be used for any period as a part of a system that treats, augments, or replaces any tissue, organ or function of the body.(G.P.T. 8th edn.-2005)
- 10. 17-10-2015
- 11. 17-10-2015
- 12. 17-10-2015
- 13. 17-10-2015
- 14. 17-10-2015 Regulations & ethics introduced Organisations like FDA,ANSI,ADA and ISO
- 15. 17-10-2015
- 16. 17-10-2015
- 17. 17-10-2015
- 18. 17-10-2015
- 19. 17-10-2015
- 21. 17-10-2015
- 22. 17-10-2015
- 24. 4-04/2021
- 25. 17-10-2015
- 26. 17-10-2015
- 27. 17-10-2015
- 28. 17-10-2015
- 29. 17-10-2015
- 30. 17-10-2015
- 31. 17-10-2015
- 32. 17-10-2015 Tests for Evaluation of Biocompatibility Biocompatibility tests are classified on three levels (tiers) :- Group I : Primary tests Group II : Secondary tests Group III : Usage tests
- 33. 17-10-2015
- 34. 17-10-2015
- 35. 17-10-2015
- 36. 17-10-2015
- 37. 17-10-2015
- 38. 17-10-2015
- 39. 17-10-2015
- 40. 17-10-2015
- 41. 17-10-2015
- 42. 17-10-2015
- 43. 17-10-2015
- 44. 4-4-2021 Australia begins coronavirus vaccine tests—AN EXAMPLE OF CLINICAL TRIAL Australia's national science agency will test two vaccine candidates over the next three months. It is part of a global race to halt the coronavirus pandemic.
- 45. Vaccination drive in India
- 46. 17-10-2015
- 47. 17-10-2015
- 48. 17-10-2015
- 49. 17-10-2015
- 50. 17-10-2015
- 51. 17-10-2015
- 52. 17-10-2015
- 53. 17-10-2015
- 54. TARNISH
- 56. 17-10-2015
- 59. 17-10-2015
- 60. 17-10-2015
- 62. 17-10-2015
- 63. 17-10-2015
- 65. 17-10-2015
- 66. 17-10-2015
- 67. 17-10-2015
- 68. 17-10-2015
- 69. 17-10-2015
- 70. Berylliosis, or chronic beryllium disease (CBD),----- is a chronic allergic-type lung response and chronic lung disease caused by exposure to beryllium and its compounds, a form of beryllium poisoning. 1. Difficulty breathing/shortness of breath 2. Weakness 3. Fatigue 4. Loss of appetite 5. Weight loss 6. Joint pain 7. Cough 8. Fever
- 71. 1. Confirm allergy by Patch test-- Avoid base metal restorations in patients with known allergy 2.Good ventilation & exhaust 3.PROTECTIVES MASKS AND GLOVES SHOULD BE WORN 4.CONSULT THE DOCTOR Berylliosis---Prevention
- 72. 17-10-2015
- 73. 17-10-2015
- 74. 17-10-2015
- 75. 17-10-2015
- 76. 17-10-2015
- 77. 17-10-2015
- 78. 17-10-2015
- 79. 17-10-2015
- 80. 17-10-2015
- 81. 17-10-2015
- 82. 17-10-2015
- 85. 17-10-2015
- 87. 17-10-2015